Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
Acadia Pharmaceuticals (Nasdaq: ACAD) has announced its participation in TD Cowen's 45th Annual Health Care Conference. The company will engage in a fireside chat on Wednesday, March 5, 2025, at 11:10 a.m. Eastern Time.
The presentation will be available through a live webcast on Acadia.com under the investors section, with an archived recording accessible for approximately one month afterward.
Acadia is a neuroscience-focused pharmaceutical company known for developing the first FDA-approved treatment for Parkinson's disease psychosis hallucinations and delusions, as well as the first approved drug in the United States and Canada for Rett syndrome. Their current clinical-stage development pipeline includes programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and various other neuroscience and neuro-rare diseases.
Acadia Pharmaceuticals (Nasdaq: ACAD) ha annunciato la sua partecipazione alla 45a Conferenza Annuale sulla Salute di TD Cowen. L'azienda parteciperà a una chiacchierata informale mercoledì 5 marzo 2025, alle 11:10 ora orientale.
La presentazione sarà disponibile tramite un webcast dal vivo su Acadia.com nella sezione dedicata agli investitori, con una registrazione archiviata accessibile per circa un mese dopo.
Acadia è un'azienda farmaceutica focalizzata sulle neuroscienze, nota per aver sviluppato il primo trattamento approvato dalla FDA per le allucinazioni e deliri nella psicosi di Parkinson, così come il primo farmaco approvato negli Stati Uniti e in Canada per la sindrome di Rett. Il loro attuale pipeline di sviluppo clinico include programmi mirati alla sindrome di Prader-Willi, alla psicosi di Alzheimer e ad altre malattie neuroscientifiche e neuro-rare.
Acadia Pharmaceuticals (Nasdaq: ACAD) ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La compañía participará en una charla informal el miércoles 5 de marzo de 2025, a las 11:10 a.m. hora del Este.
La presentación estará disponible a través de un webcast en vivo en Acadia.com en la sección de inversores, con una grabación archivada accesible durante aproximadamente un mes después.
Acadia es una empresa farmacéutica centrada en las neurociencias, conocida por desarrollar el primer tratamiento aprobado por la FDA para las alucinaciones y delirios en la psicosis de Parkinson, así como el primer medicamento aprobado en Estados Unidos y Canadá para el síndrome de Rett. Su actual pipeline de desarrollo clínico incluye programas dirigidos al síndrome de Prader-Willi, a la psicosis del Alzheimer y a diversas otras enfermedades neurocientíficas y raras.
아카디아 제약 (Nasdaq: ACAD)는 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 2025년 3월 5일 수요일 오전 11시 10분 동부 표준시(EST)에 화상 대화에 참여할 예정입니다.
프레젠테이션은 Acadia.com의 투자자 섹션을 통해 실시간 웹캐스트로 제공되며, 약 한 달 후에 아카이브된 녹화도 접근할 수 있습니다.
아카디아는 신경과학에 중점을 둔 제약 회사로, 파킨슨병 정신병의 환각과 망상에 대한 FDA 승인 치료제를 개발한 것으로 알려져 있으며, 미국과 캐나다에서 레트 증후군에 대해 승인된 첫 번째 약물입니다. 현재 임상 단계 개발 파이프라인에는 프라더-윌리 증후군, 알츠하이머병 정신병 및 다양한 기타 신경과학 및 희귀 신경 질환을 목표로 하는 프로그램이 포함되어 있습니다.
Acadia Pharmaceuticals (Nasdaq: ACAD) a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. L'entreprise participera à une discussion informelle le mercredi 5 mars 2025, à 11h10 heure de l'Est.
La présentation sera disponible via un webinaire en direct sur Acadia.com dans la section dédiée aux investisseurs, avec un enregistrement archivé accessible pendant environ un mois par la suite.
Acadia est une entreprise pharmaceutique axée sur les neurosciences, connue pour avoir développé le premier traitement approuvé par la FDA pour les hallucinations et délires dans la psychose de Parkinson, ainsi que le premier médicament approuvé aux États-Unis et au Canada pour le syndrome de Rett. Leur pipeline de développement clinique actuel comprend des programmes ciblant le syndrome de Prader-Willi, la psychose d'Alzheimer et diverses autres maladies neuroscientifiques et neuro-rares.
Acadia Pharmaceuticals (Nasdaq: ACAD) hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Das Unternehmen wird am Mittwoch, den 5. März 2025, um 11:10 Uhr Eastern Time an einem Kamin-Gespräch teilnehmen.
Die Präsentation wird über ein Live-Webcast auf Acadia.com im Bereich für Investoren verfügbar sein, mit einer archivierten Aufzeichnung, die etwa einen Monat lang zugänglich ist.
Acadia ist ein auf Neurowissenschaften fokussiertes Pharmaunternehmen, das bekannt dafür ist, die erste von der FDA genehmigte Behandlung für Psychosen bei Parkinson mit Halluzinationen und Wahnvorstellungen entwickelt zu haben, sowie das erste genehmigte Medikament in den USA und Kanada für das Rett-Syndrom. Ihr aktuelles klinisches Entwicklungsprogramm umfasst Programme, die auf Prader-Willi-Syndrom, Psychosen bei Alzheimer und verschiedene andere neurowissenschaftliche und neuro-rare Krankheiten abzielen.
- None.
- None.
A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227537305/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
When is Acadia Pharmaceuticals (ACAD) presenting at TD Cowen's Healthcare Conference 2025?
What breakthrough treatments has ACAD developed and commercialized?
What medical conditions is ACAD currently developing treatments for?
How can investors access Acadia's TD Cowen Conference presentation?
What therapeutic areas does ACAD specialize in?
